Safety & Performance of the World Medica World Diverter Embolization Device

The objective of this study is to investgiate the safety and clinical performance of the World Diverter Emoblization Device for the endovascular treatment of wide-neck (neck width ≥ 4 mm or dome-to-neck ratio <2) or fusiform intracranial aneurysms in the internal carotid artery (ICA) from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm and ≤ 5.5 mm.

Study Overview

• Status: Not yet recruiting
• Conditions: Intracranial Aneurysm
• Intervention / Treatment: Device: Flow diverter implantation

• Study Type: Interventional
• Enrollment (Estimated): 72
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain
    • Hospital Universitari Vall d'Hebron

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 22 to 80 years
• Subject, or subject's legal representative provided informed consent
• Subject agrees to the requirements of the study, including returning for required follow-up visits
• Parent artery diameter of 2.0-5.5 mm distal and proximal to the target IA
• Subject has a single target IA in the index procedure with the following characteristics: (1) Unruptured; (2) Located in the ICA from the petrous through the superior hypophyseal segments; and (3) Is a fusiform or saccular wide-necked IA with one of the following characteristics: (a) Small (< 5 mm) or medium (>5-10 mm) size with a neck width ≥ 4.0 mm or a dome-to-neck ratio of < 2; OR (b) Large (>10-25 mm) or giant (>25 mm) size

Exclusion Criteria:

• A subarachnoid or intracerebral hemorrhage in the 60 days preceding the index procedure
• A bleeding disorder or a platelet count of less than 100x103/mm3 or INR >1.5
• A contraindication to or inability to tolerate antiplatelet therapy
• An allergy to radiographic contrast agents
• An allergy to  nickel, titanium, platinum, tungsten, or stainless steel
• An allergy to local or general anesthesia
• A history of untreated atrial fibrillation, untreated/uncontrollable hypertension, or other stroke risk factors
• A history of deep vein thrombosis or pulmonary embolism
• A history of heart failure, dilated cardiomyopathy, or congenital heart conditions
• Hypercoagulopathy or a hemorrhagic or coagulation deficiency refractory to medical therapy or subject refuses treatment with blood products
• Suffered a stroke within 180 days preceding the index procedure
• Had major surgery within the 30 days preceding or planned for the 180 days following the index procedure, including but not limited to intracranial stenting or coiling
• Target aneurysm has been previously treated with clipping, coiling, or flow diversion
• Had previous stenting of or implant in parent artery proximal to the target aneurysm that could interfere with delivery or performance of study device
• Asymptomatic extradural aneurysms requiring treatment
• Contraindication to computed tomography (CT) or magnetic resonance (MR)
• An unstable neurological deficit (i.e., worsening of a clinical condition within the 30 days preceding the index procedure)
• Evidence of an active systemic infection (including COVID-19) at index procedure
• Dementia or other cognitive condition limiting their ability to participate in the study
• A condition that may limit survival to less than 12 months post-index procedure
• Serum creatinine ≥2.5 mg/dL
• Had radiation or chemotherapy treatment either currently or within the 60 days preceding the index procedure
• Current enrollment in a separate clinical trial
• Another condition(s) that, in the opinion of the Investigator, could interfere with the ability to perform a safe or effective procedure
• Current pregnancy or plan to become pregnant within the 12 months following the index procedure, or be currently breastfeeding

Angiographic Exclusion Criteria:

• Anatomy not amenable to endovascular treatment, including but not limited to severe vessel tortuosity or stenosis
• Parent vessel stenosis is >50% in the target area
• Extracranial stenosis of the carotid artery >50%
• An intracranial mass
• More than one vessel segment requiring IA treatment in the 12 months following the index procedure
• Target aneurysm is mycotic or dissecting
• Target aneurysm is at bifurcation
• Target aneurysm will require coiling in addition to flow diversion, in Investigator's opinion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: World Diverter Implantation	Device: Flow diverter implantation; Implantation of the World Diverter Embolization Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Safety - Major Adverse Events (MAEs)	Composite incidence of the following events: Major stroke (NIHSS increase of > 4) within 30 days post-procedure, defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting > 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke [i.e., intraparenchymal hemorrhage (IPH), subarachnoid hemorrhage (SAH), subdural hemorrhage (SDH), epidural hemorrhage (EDH)] accompanied with radiological evidence; Major ipsilateral stroke within 12 months post-procedure, defined as a major stroke (as defined above) occurring within the vascular distribution of the target artery; Neurological death within 12 months, defined as a death which directly resulted from a neurologic cause.	12 months
Primary Effectiveness - Complete Occlusion	The proportion of subjects with all of the following: Complete (100%) occlusion of the target IA (Raymond-Roy Class I); ≤ 50% stenosis of the parent artery at the target IA assessed by an independent Core Laboratory evaluation of angiography at 12 months post-procedure; No subsequent treatment of the target IA within 12 months post-procedure.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Medium-Term Effectiveness	Complete IA occlusion	6 months
Medium-Term Parent Artery Stenosis	Parent Artery Stenosis	6 months
Medium-Term Functional Outcomes	Modified Rankin Score (0-6, 0=no symptoms, 6=dead) compared to baseline	6 months
Secondary Effectiveness - Adequate Occlusion	The proportion of subjects with all of the following: Adequate occlusion of the target IA (Raymond-Roy Class I or II); ≤ 50% stenosis of the parent artery at the target IA assessed by an independent Core Laboratory evaluation of angiography 12 months post-procedure; No subsequent treatment of the target IA within 12 months post-procedure	12 months
Long-Term Angiographic Outcome	Raymond-Roy IA classifications	12 months
Long-Term Parent Artery Stenosis	Parent Artery Stenosis	12 months
Long-Term Functional Outcome	Modified Rankin Score (0-6, 0=no symptoms, 6=dead) compared to baseline	12 months

Collaborators and Investigators

• Sponsor: World Medica USA, LLC
• Investigators: Principal Investigator: Alejandro Tomasello, MD, Hospital Vall d'Hebron

Study record dates

Study Major Dates

• Study Start (Estimated): March 31, 2026
• Primary Completion (Estimated): March 31, 2028
• Study Completion (Estimated): August 31, 2028

Study Registration Dates

• First Submitted: January 12, 2026
• First Submitted That Met QC Criteria: January 13, 2026
• First Posted (Actual): January 14, 2026

Study Record Updates

• Last Update Posted (Actual): January 14, 2026
• Last Update Submitted That Met QC Criteria: January 13, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Intracranial Arterial Diseases; Aneurysm; Intracranial Aneurysm
• Other Study ID Numbers: CIP-001WM

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data are protected by data privacy laws and are only provided for the purposes of this study following provision of participant informed consent.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes